About petros pharmaceuticals inc - PTPI
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
PTPI At a Glance
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas
New York, New York 10036
| Phone | 1-973-242-0005 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -5,059,707.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PTPI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.117 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.059 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PTPI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,686,569.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PTPI Liquidity
| Current Ratio | 2.252 |
| Quick Ratio | 2.252 |
| Cash Ratio | 2.24 |
PTPI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -56.966 |
| Return on Equity | N/A |
| Return on Total Capital | -156.749 |
| Return on Invested Capital | N/A |
PTPI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |